GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes

International Journal of Biochemistry and Cell Biology

Volumn 37, Issue 10 SPEC. ISS., 2005, Pages 2226-2238

  Evenson, Amy R ^a   Fareed, Moin U ^a   Menconi, Michael J ^a   Mitchell, Jamie C ^a   Hasselgren, Per Olof ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Glucocorticoids; GSK 3 inhibitors; Muscle wasting; Proteolysis; Sepsis

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; DEXAMETHASONE; GLUCOCORTICOID; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; LITHIUM CHLORIDE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; 4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; 4-BENZYL-2-METHYL-1,2,4-THIADIAZOLIDINE-3,5-DIONE; ENZYME INHIBITOR; FBXO32 PROTEIN, RAT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MESSENGER RNA; MUSCLE PROTEIN; THIADIAZOLE DERIVATIVE; TRIM63 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; EXTENSOR DIGITORUM LONGUS MUSCLE; INCUBATION TIME; MALE; MUSCLE; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RAT; SEPSIS; ANIMAL; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MUSCLE CELL; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT;

ANIMALS; CELLS, CULTURED; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CHLORIDE; MALE; MUSCLE FIBERS; MUSCLE PROTEINS; MUSCLE, SKELETAL; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SEPSIS; SKP CULLIN F-BOX PROTEIN LIGASES; THIADIAZOLES; UBIQUITIN-PROTEIN LIGASES;

EID: 23944509740     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2005.06.002     Document Type: Article

References (55)

1. C.L. Antos, T.A. McKinsey, N. Frey, W. Kutschke, J. McAnally, and J.M. Shelton Activated glycogen synthase kinase-3β suppresses cardiac hypertrophy in vivo Proc. Natl. Acad. Sci. U.S.A. 99 2002 907 912
2. S.C. Bodine, E. Latres, S. Baumheuter, V.K. Lai, L. Nunez, and B.A. Clarke Identification of ubiquitin ligases required for skeletal muscle atrophy Science 294 2001 1704 1708
3. S.C. Bodine, T.N. Stitt, M. Gonzalez, W.O. Kline, G.L. Stover, and R. Bauerlein Akt/mTOR pathway is a crucial regulator of skeletal muscle hyperthrophy and can prevent muscle atrophy in vivo Nat. Cell. Biol. 3 2001 1014 1019
4. F. Bosch, J.E. Rodriguez-Gil, M. Hatzoglan, A.M. Gomez-Foix, and R.W. Hanson Lithium inhibits hepatic gluconeogenesis and phosphoenolpyruvate carboxykinase gene expression J. Biol. Chem. 267 1992 2888 2893
5. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
6. E. Chalecka-Franaszek, and D.M. Chuang Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 in neurons Proc. Natl. Acad. Sci. U.S.A. 96 1999 8745 8750
7. M.P. Coghlan, A.A. Culbert, and D.A.E. Cross Selective small-molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription Chem. Biol. 7 2000 793 803
8. D.A.E. Cross, D.R. Alessi, P. Cohen, M. Andjelkovich, and B.A. Hemmings Inhibition of glycogen synthase-3 by insulin mediated by protein kinase B Nature 378 1995 785 789
9. D.A.E. Cross, A.A. Culbert, K.A. Chahuers, L. Facci, S.D. Skaper, and A.D. Reith Selective small-molecule inhibitors of glycogen synhtase kinase-3 activity protect primary neurons from death J. Neurochem. 77 2001 94 102
10. S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 351 2000 95 105
11. H. Dudek, S.R. Datta, T.F. Franke, M.J. Birnbaum, R.J. Yao, and G.M. Cooper Regulation of neuronal survival by the serine-threonine protein kinase Akt Science 275 1997 661 665
12. C.H. Fang, B.G. Li, J.J. Wang, J.E. Fischer, and P.O. Hasselgren Treatment of burned rats with insulin-like growth factor-I inhibits the catabolic response in skeletal muscle Am. J. Physiol. 275 1998 R1091 R1098
13. C.H. Fang, B.G. Li, C.J. Wray, and P.O. Hasselgren Insulin-like growth factor-I inhibits lysosomal and proteasome-dependent proteolysis in skeletal muscle after burn injury J. Burn Care Rehab. 23 2002 318 325
14. C.H. Fang, B.G. Li, J.H. James, J.K. King, A.R. Evenson, G.D. Warden, and P.O. Hasselgren Protein muscle from burned rats is blocked by IGF-I and GSK-3β inhibitors Endocrinology 146 2005 3141 3149
15. S. Frame, and P. Cohen GSK3 takes center state more than 20 years after its discovery Biochem. J. 359 2001 1 16
16. T.F. Franke, D.R. Kaplan, and L.C. Cantley PI3K: Downstream AKTion blocks apoptosis Cell 88 1997 435 437
17. M.D. Gomes, S.H. Lecker, R.T. Jagoe, A. Navon, and A.L. Goldberg Atrogin-1, a muscle specific F-box protein highly expressed during muscle atrophy Proc. Natl. Acad. Sci. U.S.A. 98 2001 14440 14445
18. C.A. Grimes, and R.S. Jope The multifaceted roles of glycogen synthase kinase 3β in cellular signaling Progr. Neurobiol. 65 2001 391 426
19. P.O. Hasselgren Glucocorticoids and muscle catabolism Curr. Opin. Clin. Nutr. Metab. Care 2 1999 201 205
20. P.O. Hasselgren, and J.E. Fischer Muscle cachexia: Current concepts of intracellular mechanisms and molecular regulation Ann. Surg. 233 2001 9 17
21. P.O. Hasselgren, J.H. James, D.W. Benson, M. Hall-Angeras, U. Angeras, and D.T. Hiyama Total and myofibrillar protein breakdown in different types of skeletal muscle: Effects of sepsis and regulation by insulin Metabolism 38 1989 634 640
22. P.O. Hasselgren, M.A. Talamini, J.H. James, and J.E. Fischer Protein metabolism in different types of skeletal muscle during early and late sepsis in rats Arch. Surg. 121 1986 918 923
23. S. Haq, G. Choukroun, Z.B. Kang, H. Ranu, T. Matsui, and A. Rosenzweig Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy J. Cell. Biol. 151 2000 117 130
24. A. Hershko, and A. Ciechanover The ubiquitin system Annu. Rev. Biochem. 67 1998 425 479
25. S.C. Hobler, A.B. Williams, J.E. Fischer, and P.O. Hasselgren IGF-I stimulates protein synthesis but does not inhibit protein breakdown in muscle from septic rats Am. J. Physiol. 274 1998 R571 R576
26. D.H. Hong, and N.E. Forsberg Effects of dexamethasone on protein degradation and protease gene expression in rat L8 myotube cultures Mol. Cell. Endocrinol. 108 1995 199 209
27. P.S. Klein, and D.A. Melton A molecular mechanism for the effect of lithium on development Proc. Natl. Acad. Sci. U.S.A. 93 1996 8455 8459
28. S.H. Lecker, R. Jagoe, A. Gilbert, A. Gomes, V. Baracos, and J. Bailey Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression FASEB J. 18 2004 39 51
29. B.G. Li, P.O. Hasselgren, and C.H. Fang Insulin-like growth factor-I inhibits dexamethasone-induced proteolysis in cultured L6 myotubes through PI3K/Akt/GSK-3β and PI3K/Akt/mTOR-dependent mechanisms Int. J. Biochem. Cell. Biol. 37 2005 2207 2216
30. A. Martinez, M. Alonso, A. Castro, C. Perez, and F.J. Moreno First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease J. Med. Chem. 45 2002 1292 1299
31. L. Meijer, M. Flajolet, and P. Greengard Pharmacological inhibitors of glycogen synthase kinase 3 Trends Pharmacol. Sci. 25 2004 471 480
32. M.J. Menconi, W. Wei, H. Yang, C.J. Wray, and P.O. Hasselgren Treatment of cultured myotubes with the calcium ionophore A23187 increases proteasome activity via a CaMKII-caspase-calpain-dependent mechanism Surgery 136 2004 135 142
33. Y. Okuno, C.S. Huettner, H.S. Radomska, V. Petkova, H. Iwasaki, and K. Akashi Distal elements are critical for human CD34 expression in vivo Blood 100 2002 4420 4426
34. L.H. Pearl, and D. Barford Regulation of protein kinases in insulin, growth factor and Wnt signaling Curr. Opin. Struct. Biol. 12 2002 761 767
35. G. Penner, G. Gang, X. Sun, C. Wray, and P.O. Hasselgren C/EBP DNA binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle Am. J. Physiol. 282 2002 R439 R444
36. G. Piwien-Pilipuk, D. Van Mater, S.E. Ross, O.A. MacDougald, and J. Schwartz Growth hormone regulates phosphorylation and function of CCAAT/enhancer binding protein β by modulating Akt and glycogen synthase kinase-3 J. Biol. Chem. 276 2001 19664 19671
37. C.G. Proud, and R.M. Denton Molecular mechanisms for the control of translation by insulin Biochem. J. 328 1997 329 341
38. W.D. Reid, and N.A. MacGowan Respiratory muscle injury in animal models and humans Mol. Cell. Biochem. 179 1998 63 80
39. C. Rommel, S.C. Bodine, B.A. Clarke, R. Rossman, L. Nunez, and T.N. Stitt Mediation of IGF-I-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways Nat. Cell. Biol. 3 2001 1009 1013
40. W.J. Ryves, and A.J. Harwood Lithium inhibits glycogen synthase kinase-3 by competition for magnesium Biochem. Biophys. Res. Commun. 280 2001 720 725
41. J.M. Sacheck, A. Ohtsuka, S.C. McLary, and A.L. Goldberg IGF-I stimulates muscle growth by suppressing protein breakdown and expression of arophy-related ubiquitin-ligases, atrogin-1 and MuRF1 Am. J. Physiol. 287 2004 E591 E601
42. M. Sandri, C. Sandri, A. Gilbert, C. Skurk, E. Calabria, and A. Picard Foxo transcription factors induce the atrophy-related ubiquity ligase atrogin-1 and cause skeletal muscle atrophy Cell 117 2004 399 412
43. M. Shim, and R.C. Smart Lithium stabilizes the CCAAT/enhancer-bidning protein α (C/EBPα) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity J. Biol. Chem. 278 2003 19674 19681
44. T.N. Stitt, D. Drijan, B.A. Clarke, F. Panaro, Y. Timofeyva, and W.O. Kline The IGF-I/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors Mol. Cell. 14 2004 395 403
45. I. Tabata, J. Schluter, E.A. Gulve, and J.O. Holloszy Lithium increases susceptibility of muscle glucose transport to stimulation by various agents Diabetes 43 1994 903 907
46. G. Tiao, J. Fagan, V. Roegner, M. Lieberman, J.J. Wang, and J.E. Fischer Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids J. Clin. Invest. 97 1996 339 348
47. G. Tiao, J.M. Fagan, N. Samuels, J.H. James, K. Hudson, and M. Lieberman Sepsis stimulates non-lysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle J. Clin. Invest. 94 1994 2255 2264
48. T.C. Vary Regulation of skeletal muscle protein turnover during sepsis Curr. Opin. Clin. Nutr. Metab. Care 1 1998 217 224
49. T.C. Vary, G. Deiter, and S.R. Kimball Phosphorylation of eukaryotic initiation factor eIF2Bε in skeletal muscle during sepsis Am. J. Physiol. 283 2002 E1032 E1039
50. D.R. Vyas, E.E. Spangenburg, T.W. Abraha, T.E. Childs, and F.W. Booth GSK-3β negatively regulates skeletal myotube hypertrophy Am. J. Physiol. 283 2002 C545 C551
51. T.P. Waalkes, and S. Udenfriend A fluorometric method for the estimation of tyrosine in plasma and tissues J. Lab. Clin. Med. 50 1957 733 738
52. L. Wang, G.J. Luo, J.J. Wang, and P.O. Hasselgren Dexamethasone stimulates proteasome- and calcium-dependent proteolysis in cultured L6 myotubes Shock 10 1998 298 306
53. W. Wei, M.U. Fareed, A. Evenson, M.J. Menconi, H. Yang, and V. Petkova Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3 Am. J. Physiol. 288 2005 R580 R590
54. C.J. Wray, J.M. Mammen, D.D. Hershko, and P.O. Hasselgren Sepsis upregulates the expression of multiple ubiquitin ligases in skeletal muscle Int. J. Biochem. Cell. Biol. 35 2003 698 705
55. H. Yang, J. Mammen, W. Wei, M. Menconi, A. Evenson, M. Fareed, V. Petkova, and P.O. Hasselgren Expression and activity of C/EBPβ and δ are upregulated by dexamethasone in skeletal muscle J. Cell. Physiol. 204 2005 219 226